Skip to content

A prospective study of the effect of wound closure on prevention of posterior bleeding for ulcers after endoscopic submucosal dissection (ESD) in patients taking oral antithrombotic medications

A prospective study of the effect of wound closure on prevention of posterior bleeding for ulcers after endoscopic submucosal dissection (ESD) in patients taking oral antithrombotic medications - ESD study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000053726
Enrollment
25
Registered
2024-02-28
Start date
2025-01-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early Stage Gastric Cancer/Gastric Tumor

Interventions

Suture/close the ulcer bottom after gastric ESD using the MANTIS Closure Device, EZ clip.

Sponsors

Nagasaki University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Early stage gastric cancer diagnosed by preoperative endoscopy as an absolute indication for endoscopic resection or an extended indication according to the guidelines for gastric cancer treatment. (2) Early-stage gastric cancer with no clinical metastasis diagnosed by CT, echography, or other imaging methods. (3i) Male and female patients aged 20 years or older at the time of consent, who have given their written consent.

Exclusion criteria

Exclusion criteria: (1) Patients have active multiple cancers. However, intraepithelial or intramucosal carcinoma that can be cured by endoscopic treatment is eligible. (2) The patient has the following serious complications: (i) Serious hepatic disorder Serious hepatic disorder Serious cardiac disease (myocardial infarction, angina pectoris, congestive heart failure, etc.) Serious renal disorder (3) Serious infectious disease. (4) Women who are pregnant or may become pregnant. Women who are lactating. (5) Patients with serious bleeding or in shock. (6) Patients with bleeding tendency. (7) Patients who are currently participating in another clinical trial or for whom at least 3 months have not elapsed since the completion of the trial. (8) Other patients whom the investigators/associate investigators deem inappropriate as subjects.

Design outcomes

Primary

MeasureTime frame
posterior hemorrhage

Secondary

MeasureTime frame
(1) Intraoperative bleeding control (2) Lump-sum complete resection rate, lump-sum curative resection rate, lump-sum resection rate (3) MANTIS Closure Device residual duration and residual rate. (4) Incidence of thromboembolism in the perioperative period. (5) Resection time

Countries

Japan

Contacts

Public ContactKohei Sato

Nagasaki University Hospital gastroenterology

kohei3100810@gmail.com095-819-7481

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026